Oglemilast
Unit Price:
Get Latest Price
CAS No.:
778576-62-8
Content:
0.98%
Price valid (until):
2026-06-12
Company Type:
Manufactory
Location:
United States
Qualification:
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName Oglemilast Cat No CEI-1450 Description Oglemilast(GRC3886) is a potent inhibitor of PDE4. Product Overview Among the emerging agents to treat COPD or asthma, phosphodiesterase 4 (PDE4) inhibitors have attracted particular attention. PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications. Oglemilast is an orally administered inhibitor drug which is touted as an important and novel therapeutic target for asthma and chronic obstructive pulmonary disease (COPD), also known as smokers cough. Clinical trial: Glenmark Pharmaceuticals'licensing partner, Forest Laboratories, announced that the Phase IIb results on Oglemilast did not show a statistically meaningful increase from the baseline compared to the placebo (dummy drug). The markets took to this badly and the stock was pummeled on the bourses. CAS No 778576-62-8 Molecular Weight 516.3 Purity 0.98 Storage Store at -20°C Synonyms GRC 3886; GRC-3886; GRC3886 Targets PDE4 IC50 2.5 nM (PDE4B) and 1.7 nM (PDE4D) Molecular Formula C20H13Cl2F2N3O5S Chemical Name N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide Solubility Soluble in DMSO Shipping Conditions Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request In vitro Oglemilast (GRC-3886), a potent PDE4 inhibitor, inhibited PDE4 enzyme with an IC50 value of 1.4 nM and exhibited >7,000-fold selectivity over other PDE (PDE1-11) families. In human whole blood assays, oglemilast inhibited LPS-induced TNFα production with an IC50 value of 190 nM and. In vivo Oglemilast oral treatment of rats blocked Lipopolysaccharide (LPS)-induced pulmonary neu-trophilia with an ID50 of 1.45 mg/kg. In ferrets, oglemilast neither induced emesis nor caused any behavioral changes associated with emesis at 100 mg/kg. Hence, oglemilast could represent a new generation of potent selective PDE4 inhibitor with significantly improved emetic side-effect profile. category Specialty Chemicals(c26) cas_num 778576-62-8 Basic Info-
Product Name:
Oglemilast
Other Name:Oglemilast;778576-62-8;N-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methylsulfonamido)dibenzo[b,d]furan-1-carboxamide;UNII-67GXQ6WCC6;67GXQ6WCC6;N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide;Oglemilast [INN];GRC 3886;GRC-3886;SCHEMBL220245
CAS No.:778576-62-8
Molecular Formula:C20H13Cl2F2N3O5S
InChIKeys:OKFDRAHPFKMAJH-UHFFFAOYSA-N
Molecular Weight:516.3
Exact Mass:514.9921034
UNII:67GXQ6WCC6
Categories:
Characteristics -
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product